Literature DB >> 14706787

Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures.

H A Volk1, K Burkhardt, H Potschka, J Chen, A Becker, W Löscher.   

Abstract

In the brain, the efflux transporter P-glycoprotein (Pgp) is predominantly located on the luminal membrane of endothelial cells lining brain microvessels and forming the blood-brain barrier. Many lipophilic drugs, including antiepileptic drugs, are potential substrates for Pgp. Overexpression of Pgp in endothelial cells of the blood-brain barrier has been determined in patients with drug resistant forms of epilepsy such as temporal lobe epilepsy and rodent models of temporal lobe epilepsy and suggested to lead to reduced penetration of antiepileptic drugs into the brain. Expression of Pgp after seizures has also been described in astrocytes, whereas it is not clear whether neurons can express Pgp. In the present study, Pgp expression was studied by immunohistochemistry in rats 24 h after a status epilepticus induced by either pilocarpine or kainate, widely used models of temporal lobe epilepsy. Unexpectedly, in addition to endothelial Pgp staining, intense Pgp staining was found in neurons in the CA3c/CA4 sectors and hilus of the hippocampus formation, but not in other brain regions examined. The neuronal Pgp staining was confirmed by two different Pgp antibodies. Double immunolabeling and confocal microscopy showed that Pgp was colocalized with the neuronal marker neuronal nuclear antigen, but not with the glial marker glial fibrillary acidic protein. No neuronal Pgp staining was seen in control rats. The expression of Pgp in neurons after limbic seizures was substantiated by determining Pgp encoding genes (mdr1a, mdr1b) in neurons by real time quantitative RT-PCR. Increased Pgp expression in hippocampal neurons is likely to affect the action of drugs with intraneuronal targets and, in view of recent evidence from other cell types, could be associated with prevention of apoptosis which is involved in neuronal damage developing after seizures such as produced by pilocarpine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706787     DOI: 10.1016/j.neuroscience.2003.10.012

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  22 in total

Review 1.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

Review 2.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

4.  Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice.

Authors:  Markus Krohn; Cathleen Lange; Jacqueline Hofrichter; Katja Scheffler; Jan Stenzel; Johannes Steffen; Toni Schumacher; Thomas Brüning; Anne-Sophie Plath; Franziska Alfen; Anke Schmidt; Felix Winter; Katja Rateitschak; Andreas Wree; Jörg Gsponer; Lary C Walker; Jens Pahnke
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

5.  Celecoxib treatment restores pharmacosensitivity in a rat model of pharmacoresistant epilepsy.

Authors:  J Schlichtiger; A Pekcec; H Bartmann; P Winter; C Fuest; J Soerensen; H Potschka
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 6.  P-glycoprotein trafficking as a therapeutic target to optimize CNS drug delivery.

Authors:  Thomas P Davis; Lucy Sanchez-Covarubias; Margaret E Tome
Journal:  Adv Pharmacol       Date:  2014-08-23

Review 7.  Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings.

Authors:  Fionn E O'Brien; Timothy G Dinan; Brendan T Griffin; John F Cryan
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 8.  Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?

Authors:  Jens Pahnke; Lary C Walker; Katja Scheffler; Markus Krohn
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

9.  Structure-activity relationship of cyanine tau aggregation inhibitors.

Authors:  Edward Chang; Erin E Congdon; Nicolette S Honson; Karen E Duff; Jeff Kuret
Journal:  J Med Chem       Date:  2009-06-11       Impact factor: 7.446

10.  Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell cultures.

Authors:  Robert P Lisak; Joyce A Benjamins; Beverly Bealmear; Liljana Nedelkoska; Diane Studzinski; Ernest Retland; Bin Yao; Susan Land
Journal:  J Neuroinflammation       Date:  2009-01-21       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.